You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 72 Biomarker testing in patients with newly diagnosed advanced ovarian cancer – results from the first interim analysis of the non-interventional SCOUT-1 study (NOGGO Ov54, NCT04830709)

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
06. Ovarian cancer
72 Biomarker testing in patients with newly diagnosed advanced ovarian cancer – results from the first interim analysis of the non-interventional SCOUT-1 study (NOGGO Ov54, NCT04830709)
  1. Elena Ioana Braicu1,2,
  2. Pauline Wimberger2,3,
  3. Klaus Pietzner1,2,
  4. Jessika Goldmann4,
  5. Karol Kubiak5,
  6. Nikolaus De Gregorio6,
  7. Julia Caroline Radosa7,
  8. Bahriye Aktas2,8,
  9. Angelika Ober9,
  10. Cosima Brucker10,
  11. Philipp Meyer-Wilmes2,11,
  12. Badrig Melekian12,
  13. Jacqueline Sagasser2,13,
  14. Dagmar Guth14,
  15. Andreas Schnelzer15,
  16. Svetlana Tchaikovski16,
  17. Björn Lampe17,
  18. Volker Hanf18,
  19. Svenja Diemert19 and
  20. Jalid Sehouli1,2
  1. 1Department of Gynecology European Competence Center for Ovarian Cancer, Campus Virchow-Klinikum, Charité Medical University, Berlin, Germany
  2. 2North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
  3. 3Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
  4. 4Department of Obstetrics and Gynecology, DRK Kliniken Berlin, Berlin, Germany
  5. 5Department of Obstetrics and Gynecology, St. Franziskus-Hospital, Münster, Germany
  6. 6Department of Obstetrics and Gynecology, SLK Kliniken, Heilbronn, Germany
  7. 7Department of Gynecology, Obstetrics and Reproductive Medicine, University Medical School of Saarland, Homburg Saar, Germany
  8. 8Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
  9. 9Department of Obstetrics and Gynecology, St Vincenz Hospital Limburg, Limburg, Germany
  10. 10Paracelsus Medical University, University Women’s Hospital, Klinikum Nürnberg, Nürnberg, Germany
  11. 11Department of Gynecology and Obstetrics, University Hospital RWTH Aachen, Aachen, Germany
  12. 12Department of Obstetrics and Gynecology, St. Marien-Krankenhaus Siegen, Siegen, Germany
  13. 13Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
  14. 14Gynecologic Oncology, Praxis Dr. med. Dagmar Guth, Plauen, Germany
  15. 15RoMed Klinikum Rosenheim, Department of Obstetrics and Gynecology, Rosenheim, Germany
  16. 16Department of Gynecology and Obstetrics, Otto-Von-Guericke University, Magdeburg, Germany
  17. 17Department of Gynecology and Obstetrics, Florence Nightingale Hospital, Düsseldorf, Germany
  18. 18Department of Gynecology, Nathanstift, Hospital Fürth, Fürth, Germany
  19. 19AstraZeneca GmbH, Hamburg, Germany

Abstract

Introduction/Background Genomic breast cancer gene mutation (BRCAm) increases the risk for hereditary breast and/or ovarian cancer (HBOC). However, BRCAm and other homologous recombination deficiencies (HRD) also render eminent sensitivity of ovarian cancer (OC) to poly-(ADPribose)-polymerase inhibitors (PARPi). Therefore, international guidelines recommend biomarker testing to assess familial risk (blood) and to tailor individual treatment (tumour and/or blood). Real-world management of patients with primary advanced, high-grade, epithelial OC is currently being evaluated by the prospective, non-interventional study SCOUT-1 (NOGGO ov54, NCT04830709).

Methodology 750 patients with completed surgery (if applicable), eligible for platinum-based chemotherapy, tested for BRCA1/2m (solitary or within HRD-test) and provided written informed consent, are planned to be enrolled in SCOUT-1 and followed for up to 7 years. Interim analyses (IA) were defined at 175, 250 and 375 enrolled patients followed for at least 6 months. Here we present details on biomarker testing based on data from 1stIA; only descriptive statistical methods were applied.

Results Out of 175 patients considered for 1stIA (data cut-off: April 20th, 2023), 159 qualified for the Full Analysis Set (FAS). Burden for HBOC was assessed for 76.7% (N=122 patients); of these 40.2% (N=49) showed increased risk (risk score ≥ 3, DKG checklist). BRCA-test-results (blood and/or tumour) were available for 152 patients (95.6%) and BRCAm was detected in 24.3% (N=37) of the patients tested (30 with BRCA1m; 6 with BRCA2m; 1 with BRCA1&2m). Genomic BRCAm was detected in 26 patients; 16 (61.5%) of those showed an increased risk for HBOC at assessment of family history. Of all tumours tested (N=62), 45.2% (N=28) were HRD positive.

Conclusion The incidence of BRCAm and HRD observed at the time of the 1stIA is consistent with previously published data. Significant number of patients with genomic BRCAm had no increased risk according to HBOC assessment. Number of patients tested for HRD remains low.

Disclosures This study is funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

https://doi.org/10.1136/ijgc-2024-ESGO.563

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.